Could Your GLP-1 Medication Protect You From Cancer Progression?

Recent studies presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting  have brought a surprising player to the forefront of oncology research. GLP-1 medications, which were originally designed to treat metabolic disorders, could possibly reduce cancer risk. 

GLP-1 receptor agonists are widely known for managing type 2 diabetes and obesity. But after early research suggested they could also reduce the risk of cancer, more research is underway to understand just how much GLP-1s reduce risk. At the ASCO Annual Meeting, several abstracts are being presented that show how GLP-1s may affect cancer progression and even reduce the risk of developing certain cancers.

While these drugs primarily work by mimicking hormones that regulate blood sugar and appetite, emerging evidence suggests they may also play a crucial role in modulating inflammation and interacting directly with tumor biology. As researchers explore how these therapies impact both solid tumors and blood-related cancers, a new frontier in supportive and preventive cancer care is beginning to take shape.

What are GLP-1 receptor agonists, and who can take them?

GLP-1 receptor agonists (GLP-1RAs) are a class of medications that imitate the effects of a hormone called glucagon-like peptide-1. This hormone helps regulate appetite according to blood sugar levels. 

Common names include tirzepatide (Mounjaro, Zepbound), semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and orforglipron (Foundayo). Most of the GLP-1s on the market right now are weekly injections, but some are available as daily pills.  While they were initially developed as a treatment for type 2 diabetes, their clinical use has expanded rapidly due to their wide-ranging effects on the body. 

What are the indications for GLP-1 medications? 

GLP-1 medications are primarily prescribed for individuals managing type 2 diabetes, obesity, and cardiovascular disease.

These medications have multiple effects, such as improving insulin secretion, slowing gastric emptying, and, as emerging preclinical data suggests, exerting immunomodulatory effects that may influence cancer cells.

The study that may change the landscape for patients with metabolic disease and cancer risk

A groundbreaking clinical analysis on 10,225 patients diagnosed with stage I to stage III cancer who began GLP-1RA therapy after their diagnosis was presented at the ASCO Annual Meeting. In this study, a beneficial link was found between using GLP-1 medications and a lower risk of cancer spreading (metastasis).

The study tracked seven specific solid tumors: breast, prostate, lung, colorectal (CRC), liver (HCC), kidney (RCC), and pancreatic adenocarcinoma. Carrying too much weight (obesity) is considered a risk factor for all of these cancers.

The results showed a reduction in the risk of cancer progression when compared to a different diabetes medication called DPP-4 inhibitors. 

• Lung cancer: Patients had a 50% lower risk to have their cancer spread if they were on a GLP-1 compared to DPP-4i. .
• Breast cancer: Patients had a 43% lower risk.Colorectal cancer: Patients had a 31% lower risk.
• Liver cancer: Patients had a 38% lower risk.

GLP-1 and blood cancer 

Beyond solid tumors, recent research has also explored whether GLP-1 receptor agonists might protect against blood cancers. A large-scale study of over 29,000 patients with type 2 diabetes found that patients who started GLP-1 therapy had a significantly lower risk of developing several types of blood cancer compared to those taking DPP-4 inhibitors. 

Specifically, the risk of developing myelodysplastic syndromes (MDS) decreased by 30%, lymphoma risk decreased by 29%, and leukemia risk decreased by 15%. 

The protective effects of GLP-1 medications were consistent across different age groups, sexes, and races, including non-Hispanic Black, non-Hispanic White, and Hispanic patients. While more research is needed, these real-world findings suggest that GLP-1 medications may offer broad protection against both solid and hematologic cancers by helping regulate inflammation.

Why did a medication initially created for diabetes turn out to reduce cancer risk? 

Researchers also analyzed genetic data from The Cancer Genome Atlas (TCGA) to learn whether the presence of GLP-1 receptors in tumors had something to do with the cancer risk reduction after GLP-1 medications.

They found that patients with high tumor GLP-1R expression had significantly improved survival rates across all seven tumor types. This correlation was most striking in breast cancer, where high expression nearly halved the risk of mortality.

Having an adequate treatment for your metabolic disease could secondarily help reduce the risk for cancer progression

The growing evidence for GLP-1 receptor agonists suggests they may play a dual role in protecting the body against both solid tumors and blood-related cancers. By helping manage inflammation and metabolic disease, these medications have shown great results when slowing the spread of cancer cells and lowering the risk of developing new malignancies. 

While these results are exciting, it is important to remember that these are powerful medical treatments that must be carefully managed by a professional. You should never try to self-prescribe or take GLP-1 medications without a doctor's order, as they can have significant effects on your metabolism and overall health. 

If you are living with a metabolic disease like diabetes, the best way to manage your care is to keep all of your scheduled appointments with your endocrinologist. They are the experts who can determine if these therapies are right for your specific needs and ensure you are monitored safely.

Keep track of your health with HealthTree Curehub, by securely connecting your medical records you can keep track of your labs, studies and genetics all in one place. Create your account to become a cure contributor in the platform that powers lifesaving research. 

CREATE YOUR ACCOUNT

Sources: 

• Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors

• Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and hematologic cancer risk among older adults with type 2 diabetes.